American Association for Cancer Research
Browse

Table S2 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

Download (11.6 kB)
dataset
posted on 2025-02-03, 08:21 authored by Yi Sun, Luke Maggs, Apekshya Panda, Samuel J. Wright, Angelina M. Cicerchia, Anne Jenney, Matthew D. Perricone, Caitlin E. Mills, Giulia Cattaneo, Marco Ventin, Feng Chen, Martin Q. Rasmussen, Alex Miranda, Or-Yam Revach, Jacy Fang, Amina Fu, Peter J. Bowling, Tatyana Sharova, Aleigha Lawless, Peter K. Sorger, Nabeel Bardeesy, Xinhui Wang, Keith T. Flaherty, Genevieve M. Boland, Arnav Mehta, Moshe Sade-Feldman, Cristina R. Ferrone, Russell W. Jenkins

PDOTS patient data (accompanying Fig. 2)

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

TargetCancer Foundation

Cholangiocarcinoma Foundation

National Institutes of Health (NIH)

U.S. Department of Defense (DOD)

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)

History

ARTICLE ABSTRACT

Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model systems to identify and examine these factors using clinically relevant biospecimens are limited. In this study, we examined the activity of B7-H3–directed CAR T cells (B7-H3.CAR-T) using 3D microfluidic cultures of patient-derived organotypic tumor spheroids (PDOTS) and then confirmed the activity of B7-H3.CAR T cells in PDOTS. Although B7-H3 expression in PDOTS was associated with B7-H3.CAR-T sensitivity, mechanistic studies revealed dynamic upregulation of co-inhibitory receptors on CAR T-cells following target cell encounter that led to CAR T-cell dysfunction and limited efficacy against B7-H3–expressing tumors. PD-1 blockade restored CAR T-cell activity in monotypic and organotypic tumor spheroids with improved tumor control and upregulation of effector cytokines. Given the emerging role of TANK-binding kinase 1 (TBK1) as an immune evasion gene, we examined the effect of TBK1 inhibition on CAR T-cell efficacy. Similar to PD-1 blockade, TBK1 inhibition restored CAR T-cell activity in monotypic and organotypic tumor spheroids, prevented CAR T-cell dysfunction, and enhanced CAR T-cell proliferation. Inhibition or deletion of TBK1 also enhanced the sensitivity of cancer cells to immune-mediated killing. Taken together, our results demonstrate the feasibility and utility of ex vivo profiling of CAR T cells using PDOTS and suggest that targeting TBK1 could be used to enhance CAR T-cell efficacy by overcoming tumor-intrinsic and -extrinsic resistance mechanisms.

Usage metrics

    Cancer Immunology Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC